SPRED1

Across TCGA pan-cancer cohorts, SPRED1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPRED1 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher SPRED1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SPRED1 expression acts as an unfavorable survival marker.

OV, CESC, and CHOL are the cancer types where SPRED1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.082	0.844	<.001	36	view →
CESC	OS	Median	All	0.612	0.881	<.001	20	view →
CHOL	OS	Median	All	0.155	0.743	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.109	0.632	.038	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPRED1–OV (OS)

Open the OV breakdown →